Evidence map›Paper›PMID 34791123›Full record

ArticleEuropean heart journal2022

Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis.

Avirup Guha, Michael G Fradley, Susan F Dent, Neal L Weintraub, Maryam B Lustberg, Alvaro Alonso, Daniel Addison

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in European heart journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 80 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 5 pooled it
18.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 5 syntheses or guidelines pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Safety and efficacy of catheter ablation for atrial fibrillation in cancer survivors: a systematic review and meta-analysis.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2024
    Pooled it
  5. Pooled it
  6. Review
  7. Article
  8. Article
  9. Contemporary management of atrial fibrillation in patients with cancer-the 2025 European Heart Rhythm Association survey.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. The B-SCancers · 2025
    Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Avirup GuhaDepartment of Medicine, Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH 44106, USA.ORCID 0000-0003-0253-1174
Michael G FradleyCardio-Oncology Program, Division of Cardiology, Department of Internal Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA.ORCID 0000-0001-8352-8975
Susan F DentDuke Cancer Institute, Duke University, 2 Seeley Mudd, 10 Bryan Searle Drive, Durham, NC 27710, USA.ORCID 0000-0002-9183-9340
Neal L WeintraubDepartment of Medicine, Division of Cardiology, and Vascular Biology Center, Medical College of Georgia at Augusta University, 1460 Laney Walker Blvd, Augusta, GA 30912, USA.ORCID 0000-0002-5138-3705
Maryam B LustbergBreast Cancer Center, Smilow Cancer Hospital, Yale University, 35 Park St, New Haven, CT 06511, USA.
Alvaro AlonsoDepartment of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Rd, Atlanta, GA 30322, USA.ORCID 0000-0002-2225-8323
Daniel AddisonCardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, 452 W. 10th Ave. Columbus, OH 43210, USA.
Augusta University · USDuke University · USEmory University · USThe Ohio State University Wexner Medical Center · USUniversity of Pennsylvania · USYale University · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Translational Training Grant in Experimental TherapeuticsK12CA133250 · NCI · OHIO STATE UNIVERSITY · PI WILLIAM E. CARSON, Rosa Lapalombella · 2008 to 2026
$15.0M
Early Detection and Mechanisms of Cancer Immunotherapy Associated CardiotoxicityK23HL155890 · NHLBI · OHIO STATE UNIVERSITY · PI ADDISON, DANIEL · 2021 to 2024
$663k
Mentoring in patient-oriented atrial fibrillation and cardiovascular researchK24HL148521 · NHLBI · EMORY UNIVERSITY · PI ALONSO, ALVARO · 2019 to 2023
$593k
NCI NIH HHS K12 CA133250NHLBI NIH HHS K23 HL155890
6 · The paper itself

Abstract

aimsThe national incidence, risk factors, and associated mortality of atrial fibrillation (AF) in breast cancer patients are unknown. METHODS AND

resultsUsing the Surveillance, Epidemiology, and End Results-Medicare-linked database, we identified females, ≥66 years old, with a new primary diagnosis of breast cancer from 2007 through 2014. These patients were individually matched 1:1 to Medicare enrolees without cancer, and each pair was followed for 1 year to identify a primary outcome of AF. Cumulative incidence was calculated using competing risk survival statistics. Following this, identifying risk factors of AF among breast cancer patients was conducted using the adjusted Cox proportional hazards model. Finally, Kaplan-Meier methods and adjusted Cox proportional hazards modelling were performed to estimate mortality in breast cancer patients with incident and prevalent AF. This study included 85 423 breast cancer patients. Among these 9425 (11.0%) had AF diagnosis prior to the breast cancer diagnosis. New-onset AF was diagnosed in 2993 (3.9%) patients in a 1-year period after the breast cancer diagnosis [incidence 3.3%, 95% confidence interval (CI) 3.0-3.5%, at 1 year; higher rate in the first 60 days (0.6%/month)]. Comparatively, the incidence of new-onset AF in matched non-cancer controls was 1.8% (95% CI 1.6-2.0%). Apart from traditional demographic and cardiovascular risk factors, breast cancer stage was strongly associated with the development of AF [American Joint Committee on Cancer (AJCC) Stage II/III/IV vs. I: adjusted hazard ratio (aHR) 1.51/2.63/4.21, respectively]. New-onset AF after breast cancer diagnosis (aHR 3.00) is associated with increased 1-year cardiovascular mortality.

conclusionAF incidence is significantly higher in women after a breast cancer diagnosis. Higher breast cancer stages at diagnos are significantly associated with a higher risk of AF. New-onset AF in the new breast cancer diagnosis setting increases 1-year cardiovascular mortality but not breast cancer-related mortality. KEY QUESTION: What are the incidence, prevalence, risk factors and mortality outcomes of atrial fibrillation (AF) in a multi-ethnic representative United States cohort of breast cancer patients? KEY FINDING: Annual incidence for AF is 3.9% with highest rate in the first 60 days after cancer diagnosis. Cancer stage and grade are the strongest risk factors for AF. New onset AF after breast cancer increases all-cause and cardiovascular mortality. TAKE HOME MESSAGE: AF incidence is higher in breast cancer patients and is associated with later stage and grade at diagnosis of breast cancer. Involving cardio-oncology in those who develop AF after cancer diagnosis should be encouraged to improve their cardiovascular and overall prognosis.

Indexed as

Atrial FibrillationBreast NeoplasmsAgedFemaleHumansIncidenceMedicareProportional Hazards ModelsRisk FactorsUnited StatesAtrial fibrillationBreast cancerIncidenceMortalityRisk factorsSEER-Medicare

Identifiers

PMID34791123
PMCPMC8914878
OpenAlexW3214239402

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.